A biobank within the Swedish national heart failure quality registry SwedeHF.
The national heart failure quality registry SwedeHF started in 2003. It is the world's largest continuous HF registry enrolling clinician-judged HF (regardless of LVEF) at time of hospital or clinical visit. Eighty variables are entered into an electronic database managed by the Uppsala Clinical Research Center (UCR). There are \>140,000 registrations from \>110,000 unique patients from 70 hospitals in Sweden. University hospitals in Sweden with access to central biobanking will collect a high-quality biobank linked to SwedeHF consisting of blood plasma, whole blood and urine enabling genetic, proteomic and metabolomic analyses as well as analyses of different biomarkers of interest for HF patients. This will provide unique opportunities for future research within the national SwedeHF registry.
Study Type
OBSERVATIONAL
Enrollment
5,000
Karolinska University hospital
Stockholm, Sweden
RECRUITINGIdentify responders to guideline-directed medical therapy
To identify which patient will be a non-responder resulting in a poor outcome, despite being on recommended treatment according to guidelines.
Time frame: 2 and 5 years
Differences in morbidity between responders and non-responders to guideline-directed medical therapy
To characterize differences between responders and non-responders in terms of morbidity after 2-years follow-up.
Time frame: 2 years
Differences in mortality between responders and non-responders to guideline-directed medical therapy
To characterize differences between responders and non-responders in terms of mortality after 2-years follow-up.
Time frame: 2 years
Predictors of responders and non-responders to guideline-directed medical therapy
To integrate information regarding clinical characteristics, diagnostic markers and genetics to determine underlying mechanisms behind different responses to treatment.
Time frame: 2 and 5 years
Differences between responders and non-responders regarding mortality
To evaluate the differences between HFrEF and HFpEF patients in terms of mortality and after 2 and 5 years follow-up, respectively.
Time frame: 2 and 5 years
Differences between responders and non-responders regarding morbidity
o evaluate the differences between HFrEF and HFpEF patients in terms of morbidity after 2 and 5 years follow-up, respectively.
Time frame: 2 and 5 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Predictors of mortality in responders and non-responders
To evaluate the differences in mortality between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets.
Time frame: 2 and 5 years
Predictors of morbidity in responders and non-responders
To evaluate the differences in morbidity between patients with HFrEF and HFpEF by integrating information from clinical characteristics, diagnostic markers and genetics in order to have a further understanding of the underlying pathophysiology involved in HF development and prognosis with the aim to facilitate improved individualized therapy with less adverse effects and to identify novel treatment targets.
Time frame: 2 and 5 years